X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39291) 39291
Book Review (4667) 4667
Publication (2938) 2938
Newsletter (803) 803
Book Chapter (533) 533
Conference Proceeding (220) 220
Dissertation (114) 114
Magazine Article (51) 51
Book / eBook (25) 25
Web Resource (13) 13
Reference (10) 10
Government Document (8) 8
Trade Publication Article (5) 5
Newspaper Article (4) 4
Paper (4) 4
Data Set (1) 1
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32313) 32313
animals (19153) 19153
humans (16504) 16504
male (12616) 12616
rats (7066) 7066
phosphodiesterase inhibitors - pharmacology (6997) 6997
phosphodiesterase (5868) 5868
female (5824) 5824
biochemistry & molecular biology (5614) 5614
mice (4858) 4858
pharmacology & pharmacy (4750) 4750
cyclic amp - metabolism (3697) 3697
phosphodiesterase inhibitors - therapeutic use (3638) 3638
middle aged (3312) 3312
sildenafil citrate (3262) 3262
adult (2963) 2963
phosphodiesterases (2948) 2948
3',5'-cyclic-amp phosphodiesterases - metabolism (2811) 2811
kinetics (2745) 2745
neurosciences (2728) 2728
sildenafil (2683) 2683
in vitro techniques (2638) 2638
phosphoric diester hydrolases - metabolism (2587) 2587
cell biology (2585) 2585
dose-response relationship, drug (2562) 2562
phosphodiesterase inhibitors (2520) 2520
cells, cultured (2515) 2515
erectile dysfunction (2389) 2389
research (2369) 2369
erectile dysfunction - drug therapy (2300) 2300
aged (2212) 2212
enzymes (2209) 2209
expression (2127) 2127
signal transduction (2045) 2045
abridged index medicus (2040) 2040
camp (2009) 2009
cyclic gmp - metabolism (2000) 2000
analysis (1991) 1991
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (1975) 1975
phosphorylation (1954) 1954
urology & nephrology (1880) 1880
proteins (1808) 1808
time factors (1772) 1772
activation (1767) 1767
sphingomyelin phosphodiesterase - metabolism (1760) 1760
cells (1725) 1725
rats, sprague-dawley (1718) 1718
cattle (1715) 1715
molecular sequence data (1696) 1696
treatment outcome (1658) 1658
piperazines - therapeutic use (1631) 1631
purines (1618) 1618
physiological aspects (1551) 1551
physiology (1546) 1546
sulfones (1523) 1523
calcium - metabolism (1491) 1491
cardiac & cardiovascular systems (1491) 1491
disease models, animal (1447) 1447
inhibition (1426) 1426
nitric oxide (1425) 1425
cyclic amp (1420) 1420
cell line (1415) 1415
rats, wistar (1414) 1414
amino acid sequence (1409) 1409
enzyme inhibitors - pharmacology (1401) 1401
tadalafil (1395) 1395
article (1393) 1393
nitric-oxide (1371) 1371
1-methyl-3-isobutylxanthine - pharmacology (1332) 1332
apoptosis (1292) 1292
phosphodiesterase 5 inhibitors - therapeutic use (1269) 1269
impotence (1266) 1266
rolipram (1256) 1256
chemistry, medicinal (1233) 1233
enzyme activation (1203) 1203
phosphodiesterase inhibitors - administration & dosage (1192) 1192
mice, inbred c57bl (1170) 1170
mutation (1158) 1158
inhibitors (1152) 1152
adenylyl cyclases - metabolism (1146) 1146
cgmp (1142) 1142
gene expression (1133) 1133
piperazines - pharmacology (1126) 1126
identification (1094) 1094
brain (1081) 1081
3',5'-cyclic-gmp phosphodiesterases - metabolism (1071) 1071
inflammation (1067) 1067
rabbits (1040) 1040
calcium (1033) 1033
cyclic nucleotide phosphodiesterases, type 4 (1026) 1026
biophysics (1024) 1024
in-vitro (1019) 1019
structure-activity relationship (1016) 1016
health aspects (1011) 1011
phosphodiesterase inhibitors - adverse effects (1004) 1004
hydrolysis (991) 991
multidisciplinary sciences (986) 986
cyclic-nucleotide phosphodiesterases (967) 967
respiratory system (950) 950
base sequence (948) 948
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (12) 12
Online Resources - Online (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Theses (1) 1
University Archives - Archives (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38458) 38458
German (476) 476
Russian (475) 475
Japanese (317) 317
French (282) 282
Chinese (217) 217
Spanish (177) 177
Italian (54) 54
Portuguese (47) 47
Polish (38) 38
Korean (31) 31
Swedish (16) 16
Hungarian (15) 15
Turkish (15) 15
Czech (14) 14
Dutch (12) 12
Danish (10) 10
Hebrew (9) 9
Norwegian (8) 8
Finnish (7) 7
Croatian (6) 6
Ukrainian (6) 6
Bulgarian (4) 4
Slovak (4) 4
Serbian (3) 3
Romanian (2) 2
Slovenian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1992, ISBN 0881678201, Volume 25., xvii, 429 p. : ill. ; 24 cm.
Book
Nature Biotechnology, ISSN 1087-0156, 01/2010, Volume 28, Issue 1, pp. 63 - 70
Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions. Here we present seven... 
CAMP-SPECIFIC PHOSPHODIESTERASE | PHOSPHORYLATION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | PROTEIN-KINASE | GENE COMPOSER | SUNCUS-MURINUS | AMP-SPECIFIC PHOSPHODIESTERASE | INHIBITORS | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | ROLIPRAM BINDING | ANTIDEPRESSANT DRUGS | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Humans | Molecular Sequence Data | Crystallography, X-Ray | Structure-Activity Relationship | Benzhydryl Compounds - chemistry | Benzhydryl Compounds - adverse effects | Phenylurea Compounds - adverse effects | Phenylurea Compounds - chemistry | Drug Design | Phosphodiesterase 4 Inhibitors | Behavior, Animal - drug effects | Biological Assay | Phosphodiesterase Inhibitors - chemistry | Benzhydryl Compounds - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Disease Models, Animal | Allosteric Regulation - drug effects | Protein Structure, Tertiary | Amino Acid Sequence | Cell Line | Catalytic Domain | Models, Molecular | Phenylurea Compounds - therapeutic use | Phosphodiesterase Inhibitors - pharmacology | Vomiting - drug therapy | Cognition - drug effects | Animals | Benzhydryl Compounds - pharmacology | Mice | Phenylurea Compounds - pharmacology | Kinetics | Care and treatment | Schizophrenia | Physiological aspects | Genetic aspects | Cellular signal transduction | Cyclic adenylic acid | Research | Phosphodiesterases | Enzymes | Biotechnology | Cellular biology | Molecular biology | Cognitive ability | Crystal structure | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/1999, Volume 127, Issue 1, pp. 65 - 74
The effects of several phosphodiesterase (PDE) inhibitors on the L‐type Ca current ( I Ca ) and intracellular cyclic AMP concentration ([cAMP] i ) were... 
cilostamide (PDE3 inhibitor) | intracellular cyclic AMP | phosphodiesterase subtypes | current | Ro20‐1724 (PDE4 inhibitor) | L‐type Ca | EHNA (PDE2 inhibitor) | phosphodiesterase inhibitors | MIMX (PDE1 inhibitor) | β‐adrenoceptor agonist | Rat heart | Cilostamide (PDE3 inhibitor) | β-adrenoceptor agonist | Intracellular cyclic AMP | Phosphodiesterase subtypes | L-type Ca | Phosphodiesterase inhibitors | Ro20-1724 (PDE4 inhibitor) | MYOCARDIUM | CELLS | ISOFORMS | BIOCHEMISTRY & MOLECULAR BIOLOGY | L-type Ca2+ current | beta-adrenoceptor agonist | CARDIAC MYOCYTES | CALCIUM CURRENT | rat heart | DEPENDENT PROTEIN-KINASE | FATTY-ACIDS | AMP PHOSPHODIESTERASES | GMP | PHARMACOLOGY & PHARMACY | HUMAN ATRIAL MYOCYTES | Cyclic Nucleotide Phosphodiesterases, Type 1 | Heart Ventricles - cytology | Calcium Channels - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 | Rats, Wistar | Cyclic Nucleotide Phosphodiesterases, Type 3 | Calcium Channels, L-Type | Male | 3',5'-Cyclic-AMP Phosphodiesterases - physiology | Cyclic AMP - physiology | 3',5'-Cyclic-AMP Phosphodiesterases - biosynthesis | Calcium - physiology | Heart Ventricles - enzymology | Myocardium - metabolism | 3',5'-Cyclic-GMP Phosphodiesterases - biosynthesis | 3',5'-Cyclic-GMP Phosphodiesterases - physiology | Adrenergic beta-Agonists - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Rats | Reverse Transcriptase Polymerase Chain Reaction | Myocardium - cytology | Phosphoric Diester Hydrolases | Myocardium - enzymology | Patch-Clamp Techniques | Animals | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Isoproterenol - pharmacology | Heart Ventricles - metabolism | In Vitro Techniques | Index Medicus | Papers
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2008, Volume 105, Issue 49, pp. 19532 - 19537
Cyclic nucleotide phosphodiesterase (PDE) isoforms can influence disease pathogenesis and be novel therapeutic targets. Because lower cAMP levels may... 
Protein isoforms | T lymphocytes | Chronic lymphocytic leukemia | Messenger RNA | Cyclic nucleotides | B lymphocytes | Medical treatment | Apoptosis | Vehicles | B cell leukemia | B cell | Survivin | cAMP | survivin | CELLS | CAMP-SPECIFIC PHOSPHODIESTERASE | AMP | INHIBITOR-INDUCED APOPTOSIS | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | apoptosis | HUMAN B-LYMPHOCYTES | THEOPHYLLINE | PATHWAY | THERAPEUTIC TARGET | GENE-EXPRESSION | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 4 | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | RNA, Messenger - metabolism | Enzyme Activation - immunology | Cell Division - immunology | Cyclic Nucleotide Phosphodiesterases, Type 7 - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology | Membrane Potential, Mitochondrial | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Cyclic AMP-Dependent Protein Kinases - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | B-Lymphocytes - cytology | B-Lymphocytes - enzymology | Phosphodiesterase 3 Inhibitors | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Phosphodiesterase Inhibitors - pharmacology | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Gene Expression Regulation, Leukemic | Gene Expression Regulation, Enzymologic | Apoptosis - immunology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors | Physiological aspects | Genetic aspects | Cyclic adenylic acid | Research | Drug therapy | Phosphodiesterases | Enzymes | Protein folding | Leukemia | Gene expression | Ribonucleic acid--RNA | Cells | Index Medicus | Biological Sciences
Journal Article
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7544, pp. 472 - 476
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 03/2015, Volume 403, Issue C, pp. 10 - 20
Journal Article
Circulation: Arrhythmia and Electrophysiology, ISSN 1941-3149, 06/2018, Volume 11, Issue 6, pp. e005896 - e005896
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 01/2013, Volume 23, Issue 1, pp. 375 - 381
(−)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5- ]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2 )-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory... 
Phosphodiesterase (PDE) | Inhaled administration | Dual PDE3/4 inhibitor | Asthma | COPD | MORTALITY | CHRONIC HEART-FAILURE | BRONCHODILATORY ACTIVITY | DESIGN | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | 4,5-DIHYDRO-6-<4-(1H-IMIDAZOL-1-YL)PHENYL>-3(2H)-PYRIDAZINONES | OBSTRUCTIVE PULMONARY-DISEASE | POSITIVE INOTROPIC AGENTS | CORTICOSTEROIDS | CARDIOTONIC AGENTS | ROFLUMILAST | Cyclic Nucleotide Phosphodiesterases, Type 3 - chemistry | Phosphodiesterase 3 Inhibitors - chemistry | Phosphodiesterase 3 Inhibitors - pharmacology | Pyridines - chemistry | Structure-Activity Relationship | Phosphodiesterase 4 Inhibitors - chemical synthesis | Bronchodilator Agents - chemistry | Drug Design | Bronchoalveolar Lavage Fluid - cytology | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Phosphodiesterase 4 Inhibitors - chemistry | Anti-Inflammatory Agents - pharmacology | Administration, Inhalation | Rats | Bronchodilator Agents - pharmacology | Bronchodilator Agents - chemical synthesis | Phosphodiesterase 4 Inhibitors - pharmacology | Pyridazines - chemistry | Phosphodiesterase 3 Inhibitors - chemical synthesis | Animals | Anti-Inflammatory Agents - chemistry | Protein Binding | Leukocytes - drug effects | Anti-Inflammatory Agents - chemical synthesis | Anti-inflammatory drugs | Respiratory agents | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 3, pp. 238 - 248
Background - Sildenafil was recently approved for the treatment of pulmonary arterial hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5)... 
Inhibitors | Inotropic agents | Contractility | Hypertension, pulmonary | Hypertrophy | inhibitors | CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL SILDENAFIL | hypertrophy | PULMONARY ARTERIAL-HYPERTENSION | contractility | HEART-FAILURE | SILDENAFIL CITRATE | pulmonary | DEPENDENT PROTEIN-KINASE | NATRIURETIC PEPTIDE | INHALED NITRIC-OXIDE | CYCLIC-GMP PHOSPHODIESTERASE | inotropic agents | IN-VITRO | PERIPHERAL VASCULAR DISEASE | CARDIAC CONTRACTILITY | HEMATOLOGY | hypertension | Gene Expression Regulation, Enzymologic - drug effects | Phosphodiesterase Inhibitors - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 5 | 3',5'-Cyclic-GMP Phosphodiesterases - genetics | Humans | Middle Aged | Myocardial Contraction - physiology | Child, Preschool | Myocardial Contraction - drug effects | Phosphodiesterase Inhibitors - pharmacology | Rats | Infant | Male | Gene Expression Regulation, Enzymologic - physiology | Hypertrophy, Right Ventricular - enzymology | Rats, Sprague-Dawley | Hypertrophy, Right Ventricular - drug therapy | Animals | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Adult | Female | 3',5'-Cyclic-GMP Phosphodiesterases - biosynthesis | Infant, Newborn | Physiological aspects | Care and treatment | Phosphodiesterases | Pulmonary hypertension | Heart ventricle, Right | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Molecular and Cellular Cardiology, ISSN 0022-2828, 2015, Volume 88, pp. 29 - 38
Abstract In cardiac myocytes, the second messenger cAMP is synthesized within the β-adrenergic signaling pathway upon sympathetic activation. It activates... 
Cardiovascular | β-adrenergic pathway | Cyclic nucleotides | Computational model | Signaling networks | Cardiac myocytes | Phosphodiesterase | CARDIAC & CARDIOVASCULAR SYSTEMS | COMPUTATIONAL MODELS | HEART-FAILURE | beta-adrenergic pathway | CAMP EARLY REPRESSOR | CGMP PHOSPHODIESTERASES | PROTEIN-KINASES | FEEDBACK LOOP | CELL BIOLOGY | CARDIOMYOCYTE APOPTOSIS | NITRIC-OXIDE | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | RAT VENTRICULAR MYOCYTES | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Phosphorylation | Humans | Myocardial Contraction - physiology | Cyclic Nucleotide Phosphodiesterases, Type 2 - genetics | Cyclic AMP-Dependent Protein Kinases - genetics | Myocardium - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Binding Sites | Cyclic AMP - metabolism | Binding, Competitive | Cyclic AMP-Dependent Protein Kinases - metabolism | Myocytes, Cardiac - cytology | Signal Transduction | Models, Cardiovascular | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Gene Expression Regulation | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Feedback, Physiological | Animals | Cyclic GMP - metabolism | Myocytes, Cardiac - metabolism | Protein Binding | Mice | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Index Medicus
Journal Article